biostudies-literatureUnknown9(2)Ju H<h4>Importance</h4>The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.<h4>Objective</h4>To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.<h4>Design, setting, and participants</h4>This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.<h4>Exposure</h4>Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).<h4>Main outcomes and measures</h4>The primary outcomes were time to first relapse in patients with a disease duJAMA network opene2559471https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905660biostudies-literatureDisability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.PMC12905660Kim SWShin HYJu WLee SKim HLee TKOh JNam TSSohn EAhn SWPark MSLee HSPark JWKim SHOh SILee HLSeok JMKim KHKang YRChung YHKim SMKwon SYang JOh SYKim HJBae JSKim JKYoon BAWoo SYKim BJLim YMSeok HYJu HKim SBong JBMin JHLee EJKim WJoo ISKwon YNKim JEKim NHfalseDisability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.<h4>Importance</h4>The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.<h4>Objective</h4>To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.<h4>Design, setting, and participants</h4>This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.<h4>Exposure</h4>Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).<h4>Main outcomes and measures</h4>The primary outcomes were time to first relapse in patients with a disease du2026-01-01T00:00:00Z2026 Feb2026-07-15T15:44:39.248Z2026-07-06T03:11:58.962ZS-EPMC129056604168643510.1001/jamanetworkopen.2025.59471